Abstract 84P
Background
To modify the tumor burden score (TBS) and to develop a comprehensive and practical prognostic scoring system among Chinese patients with colorectal liver metastases (CRLM).
Methods
787 adult patients who underwent curative-intent liver resection for CRLM were identified from Zhongshan Hospital in Shanghai, China between June 2010 and January 2018. Tumor relapse-free survival (RFS) was the main outcomes. TBS was modified with geometric algorithms. The Cox regression model was used to identify independent predictors of prognosis. Time-dependent AUC, calibration curve, and C-index were employed to validate the predictive ability of a survival model.
Results
Modified TBS (mTBS) was established by a mathematical equation (parameters were CRLM size, CRLM number, and unilobar/bilobar metastasis). mTBS model (AUC=0.62 at 33 Month) out-performed TBS model (AUC=0.54 at 33 Month) in predicting RFS (P=.002). Five preoperative predictors of worse RFS were identified and were incorporated into CERR score: KRAS/NRAS/BRAF mutated tumor (score 1 point); node-positive primary (1 point); extrahepatic disease (1 point); CEA level >200 ng/ml or CA 19-9 >200 U/mL (1 point); mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients undergoing hepatectomy for CRLM were stratified by CERR score into risk groups: high-risk group (CERR score 4 or more) had a 3-year RFS rate of 9.77%; medium-risk group (CERR score 2-3) had a 3-year RFS rate of 21.96%; low-risk group (CERR score 0-1) had a 3-year RFS rate of 39.90%. The CERR score model was further validated using internal bootstrap validation, and the discriminatory capacity of the CERR score was significantly superior to that of the Fong score and that of the Genetic and Morphological Evaluation (GAME) score.
Conclusions
Modified TBS should be promoted. The CERR score is a powerful prognostic tool that can help to determine the optimal clinical management strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract